Despite recent positive outcomes in clinical trials with therapeutics for the treatment of atherosclerosis, namely those based on monoclonal antibodies against IL-1β and PCSK9 (Ridker et al., 2017; Sabatine et al., 2017), this disease remains the leading cause of death worldwide. This evidence concerns the gene IL1B and atherosclerosis.